BioForce Nanosciences Holdings, Inc.
BFNH · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -4.69 | 41.39 | 41.03 | 0.70 |
| FCF Yield | -0.61% | -0.08% | -0.12% | -0.22% |
| EV / EBITDA | -20.38 | 0.00 | -120.33 | -70.19 |
| Quality | ||||
| ROIC | 24.19% | 25.94% | 36.04% | 58.24% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.12 | 0.10 | 0.14 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -31.15% | 31.71% | 12.06% | 3.02% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -0.36 | -0.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |